Biohaven's Stock Surges as FDA Cancels Advisory Committee Meeting for Lead Drug Troriluzole

Biohaven Pharmaceuticals' shares surged in the premarket after the FDA cancelled an advisory committee meeting related to its marketing application for lead drug troriluzole. The company received priority review from the FDA earlier this year for troriluzole, which is being developed for the treatment of amyotrophic lateral sclerosis (ALS). The cancellation of the meeting suggests that the FDA may approve the drug without further scrutiny.

Biohaven Pharmaceuticals' shares surged in the premarket on July 2, 2025, following the Food and Drug Administration's (FDA) cancellation of an advisory committee meeting related to its marketing application for lead drug troriluzole. The company received priority review from the FDA earlier this year for troriluzole, which is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

The cancellation of the meeting suggests that the FDA may approve the drug without further scrutiny. RBC Capital Markets analyst Leonid Timashev noted that such cancellations have historically been "modestly encouraging" for Biohaven, as the FDA subsequently green-lit the drugs under review in roughly two-thirds of cases [1].

Biohaven Pharmaceuticals' common shares are listed on the New York Stock Exchange under the ticker (NYSE:BHVN). The company maintains a solid liquidity position with a current ratio of 3.82x, though it faces profitability challenges [2].

References:
[1] https://www.biopharmadive.com/news/biohaven-adcomm-canceled-catalent-layoffs-stealth-resubmission/758184/
[2] https://www.investing.com/news/sec-filings/biohaven-says-fda-will-not-hold-advisory-meeting-for-troriluzole-application-93CH-4206547